Advertisement
U.S. markets open in 8 hours 8 minutes
S&P Futures
5,888.75 -3.75 (-0.06%) Dow Futures
43,047.00 -122.00 (-0.28%) Nasdaq Futures
20,525.25 -16.75 (-0.08%) Russell 2000 Futures
2,244.70 -1.50 (-0.07%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,764.40 +4.60 (+0.17%)
Unicycive Therapeutics, Inc. (UNCY)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 0.4347 |
| Open | 0.4300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4200 - 0.4421 |
| 52 Week Range | 0.2020 - 1.8180 |
| Volume | |
| Avg. Volume | 2,304,542 |
| Market Cap | 40.668M |
| Beta (5Y Monthly) | 2.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
GlobeNewswireUnicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website un
Clinical Trials ArenaResults of Phase I trial shed positive light on UNI-494 for acute kidney injury
The ageing global population will lead to an increase in acute kidney injury and a growing need for more therapeutic options.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.